Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.500
+0.030 (1.21%)
Mar 25, 2026, 4:00 PM EDT - Market closed

Neumora Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-236.3-243.79-235.93-130.9-237.31-99.27
Depreciation & Amortization
0.360.630.670.590.540.11
Stock-Based Compensation
32.3739.9917.248.34.271.68
Other Adjustments
-0.6-2.4163.6414.06158.0473.86
Changes in Accounts Payable
-6.582.87-0.58-1.25-0.76-4.67
Changes in Accrued Expenses
6.057.246.49-1.626.562.4
Changes in Other Operating Activities
-0.9412.53-14.8-4.08-6.76-0.85
Operating Cash Flow
-208.83-182.94-163.28-114.9-75.42-26.76
Capital Expenditures
---0.12-0.51-0.82-1.3
Sale of Property, Plant & Equipment
0.13-----
Purchases of Investments
-189.77-312.22-109.07-226.37--12.75
Proceeds from Sale of Investments
216.69242.44178.1771.87--
Payments for Business Acquisitions
--0.78-4.59-13--
Other Investing Activities
-----2.81
Investing Cash Flow
27.08-70.5664.39-168.01-0.82-11.24
Long-Term Debt Issued
9.06----55.91
Net Long-Term Debt Issued (Repaid)
9.06----55.91
Issuance of Common Stock
1.7121.6236.234.273.473.19
Repurchase of Common Stock
---0.49---0
Net Common Stock Issued (Repurchased)
1.7121.6235.744.273.473.19
Issuance of Preferred Stock
---112.22291.18171.01
Net Preferred Stock Issued (Repurchased)
---112.22291.18171.01
Other Financing Activities
0.23--3.8-0.74-1.14-
Financing Cash Flow
33.8921.6231.94115.74293.51230.1
Net Cash Flow
-147.86-231.89133.05-167.17217.27192.1
Free Cash Flow
-208.83-182.94-163.4-115.41-76.24-28.06
Free Cash Flow Per Share
-1.29-1.15-2.51-4.24-3.48-2.16
Levered Free Cash Flow
-232.38-220.52-244.27-137.77-238.55-47.69
Unlevered Free Cash Flow
-250.88-240.39-260.73-142.74-238.56-99.84
Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q